Overview

Choosing immunotherapy candidates by tumor histology alone leaves many responders untreated, which is why biomarker testing now drives PD-1 blockade. Pembrolizumab (Keytruda) 100 mg/4 mL injection is used across multiple tumors selected by PD-L1 expression, microsatellite instability, or tumor mutational burden. For B2B buyers the addressable population depends directly on how widely the destination market performs these tests. We support distributors with clear guidance on which biomarkers define the eligible cohort. Matching supply to tested patient volume prevents both shortages and overstock.

How It Works

Pembrolizumab is a monoclonal antibody that blocks PD-1, the receptor tumors exploit to silence attacking lymphocytes. By occupying PD-1 it restores the ability of T cells to recognize and eliminate cancer cells. The clinical effect is therefore contingent on a pre-existing immune infiltrate, which is why biomarker selection matters. From a procurement perspective, demand concentrates wherever PD-L1 scoring and genomic instability testing are routinely available. Distributors should link forecasts to local testing throughput.

Indications

The 100 mg/4 mL presentation is indicated across a range of PD-1-responsive tumors, including those defined by PD-L1 TPS thresholds, MSI-H status, or high mutational burden. Eligibility must be confirmed with the relevant assay per the local label. Confirming the approved tumor types and where the product sits in the treatment sequence is required per country. We supply the concentrated injection format suited to weight-based dosing.

Dosage & Administration

Pembrolizumab is given as an intravenous infusion, commonly 200 mg every three weeks or a weight-based alternative per the prescriber. It is administered in a clinical setting by trained staff using aseptic technique. Because scheduling is periodic rather than daily, procurement should align deliveries with the infusion calendar. We recommend confirming the expected number of cycles before placing a bulk order.

Storage & Sourcing

Store the injection at 2-8°C and protect it from light; do not freeze. Our cold-chain export uses validated insulated packaging with temperature logging for every consignment. Minimum order quantities and lead times are set per destination and registration status. Each delivery includes the batch-release certificate and analytical documentation required for customs and pharmacy acceptance.

FAQ

Q: Which biomarkers define the eligible patient population? PD-L1 TPS score, MSI-H status, and high tumor mutational burden are the main selectors used across the licensed indications.

Q: How should distributors forecast demand for an infusion product? Base the forecast on local PD-L1 and MSI testing volume and the infusion center's treatment calendar.

Q: Is cold-chain handling mandatory for this injection? Yes. The concentrate must be kept at 2-8°C with light protection throughout transit and storage.

Q: Can the product be used across different tumor types? Within each market it is limited to the biomarker-defined indications approved on the local label.